Andrea Kwakowsky

Auckland, AUK, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Development-related gene expression disruption in the human midcingulate cortex in Huntington's disease.

Development-related gene expression disruption in the human midcingulate cortex in Huntington's disease.

Journal: Journal of Huntington's disease

Published: May 04, 2026

Bumetanide as a potential treatment for neurodegenerative and neurodevelopmental disorders: A systematic review.

Bumetanide as a potential treatment for neurodegenerative and neurodevelopmental disorders: A systematic review.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 17, 2026

Rebalancing inhibition: α5 GABAA receptor positive and negative allosteric modulation in Alzheimer's disease.

Rebalancing inhibition: α5 GABAA receptor positive and negative allosteric modulation in Alzheimer's disease.

Journal: Experimental and molecular pathology

Published: February 12, 2026

Estren prevents beta-amyloid-induced basal forebrain cholinergic loss and long-term spatial memory deficits in aged female mice.

Estren prevents beta-amyloid-induced basal forebrain cholinergic loss and long-term spatial memory deficits in aged female mice.

Journal: Scientific reports

Published: January 29, 2026

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?

Journal: International journal of molecular sciences

Published: December 09, 2025

The β-amyloid-induced increased tonic conductance, impaired long-term potentiation and cognitive deficits characteristic of Alzheimer's disease are reversed by an α5 inverse agonist of the GABA type A receptor.

The β-amyloid-induced increased tonic conductance, impaired long-term potentiation and cognitive deficits characteristic of Alzheimer's disease are reversed by an α5 inverse agonist of the GABA type A receptor.

Journal: Neuropharmacology

Published: September 04, 2025

Remodeling of the glutamatergic system in the Alzheimer's disease medial temporal lobe and superior temporal gyrus.

Remodeling of the glutamatergic system in the Alzheimer's disease medial temporal lobe and superior temporal gyrus.

Journal: Neural regeneration research

Published: August 09, 2025

Exploration of the genetic neuroinflammatory environment in the human midcingulate cortex in Huntington's disease.

Exploration of the genetic neuroinflammatory environment in the human midcingulate cortex in Huntington's disease.

Journal: Communications medicine

Published: June 08, 2025

Potential of in vitro microelectrode arrays in Alzheimer's disease research.

Potential of in vitro microelectrode arrays in Alzheimer's disease research.

Journal: Neural regeneration research

Published: December 12, 2024

Hormone Replacement Therapy and Alzheimer's Disease: Current State of Knowledge and Implications for Clinical Use.

Hormone Replacement Therapy and Alzheimer's Disease: Current State of Knowledge and Implications for Clinical Use.

Journal: Journal of Alzheimer's disease : JAD

Published: October 18, 2024

Upregulated excitatory amino acid transporter 1 (EAAT1) expression in the human medial temporal lobe in Alzheimer's disease.

Upregulated excitatory amino acid transporter 1 (EAAT1) expression in the human medial temporal lobe in Alzheimer's disease.

Journal: Neuroscience

Published: September 09, 2024

β-amyloid's neurotoxic mechanisms as defined by in vitro microelectrode arrays: a review.

β-amyloid's neurotoxic mechanisms as defined by in vitro microelectrode arrays: a review.

Journal: Pharmacological research

Published: May 17, 2024

Showing 1-12 of 62

Last Updated: 09/26/2026